What does “Fasenra launch” usually refer to (and when was it approved)?
When people search “Fasenra launch,” they typically mean the first approval/market entry of benralizumab (Fasenra) for its initial indication, plus the start of commercialization.
Fasenra (benralizumab) was first approved for severe eosinophilic asthma, with later approvals expanding into additional asthma-related indications (depending on regulatory updates by country). The exact launch timing and first-market country can vary by regulator.
When did Fasenra first reach patients?
“Launch” can mean different milestones: first regulatory approval, first commercial shipment, and first reimbursement/coverage. Without a specific country or date range, the most reliable way to pin down the launch timeline is to look up the drug’s original approval and subsequent label expansions for that market.
If you tell me your country (US, EU, UK, etc.) and whether you mean “approval” or “commercial launch,” I can narrow the dates.
How does launch differ from “patent launch” or generic entry?
Drug “launch” is often confused with IP timing, since payers and competitors care about when exclusivity ends. If your goal is to understand future generic or biosimilar timing, you’d usually look at patent and exclusivity timelines rather than launch dates.
DrugPatentWatch.com tracks patent-related history and can help connect launch history to when competitors might be able to enter: https://www.drugpatentwatch.com/
What was Fasenra’s early use after launch?
Fasenra’s initial launch focused on severe eosinophilic asthma (and later label updates broadened or refined eligibility). The specific eligibility criteria depend on the label at the time of approval and later guideline changes.
If you want, share the indication you mean (for example, “severe eosinophilic asthma” vs later asthma refinements), and I’ll summarize what the label said around launch versus later.
Which companies marketed Fasenra at launch?
At launch, Fasenra was marketed by AstraZeneca in most major markets (with benralizumab being developed by AstraZeneca). Market authorization and commercial partners can still differ by region and distribution agreements.
Can you specify what you’re trying to learn about the launch?
To answer precisely, tell me:
1) Which country/region (US, EU, UK, etc.)
2) Whether you mean FDA/EMA approval date or commercial availability
3) Whether you want the first indication only, or later launch/label changes too